itriglumide

Itriglumide (CR-2945) is a potent and selective non-peptide antagonist of the cholecystokinin-2 (CCK-2) receptor, also known as the CCK-B receptor. Developed by Rottapharm S.p.A. (later Meda, now Viatris) as an anthranilic acid derivative, itriglumide was primarily investigated for its ability to inhibit gastrin-induced gastric acid secretion. Clinical development reached Phase II for several acid-related gastrointestinal disorders, including gastroesophageal reflux disease (GERD), peptic ulcers, and functional dyspepsia. Due to the wide distribution of CCK-2 receptors in the central nervous system, itriglumide was also explored for the treatment of generalized anxiety disorder (GAD) and obstructive sleep apnea syndrome. Despite its broad clinical program, development appears to have ceased, and the drug is currently considered discontinued.

Other names

(R)-1-naphthalenepropanoic acid-beta-((2-((2-(8-azaspiro(4.5)dec-8-ylcarbonyl)-4,6-dimethylphenyl)amino)-2-oxoethyl)amino)itriglumidaitriglumidum